MBJ: Australian operation acquires part of local cancer research company
An Australian full-service contract research organization (CRO) acquired part of a Memphis oncology research and data analytics company.
Australia’s George Clinical announced its acquisition of Vector Oncology’s CRO division.
Under the arrangement, Sean Hart, executive vice president and managing director of Vector Oncology, will lead George Clinical’s U.S. operations and global study offerings.
“It is difficult to find two companies more suited to each other,” Hart said in a release. “The marriage of scientific and operational excellence has been a core value of Vector Oncology since the organization’s inception. [Vector president] Dr. Lee Schwartzberg and [senior medical director] Dr. Ari VanderWalde will continue in their roles as scientific leaders and consultants in oncology research under the George Clinical banner. We are confident that the foundations of scientific, operational and personal excellence will be continued and strengthened under this new arrangement.”
Schwartzberg is also the medical director at The West Cancer Center.
The merger will strengthen George Clinical’s ability to provide oncology trial delivery solutions in the Asia-Pacific region, as well as expand the company’s operational expertise and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology, throughout the United States.
George Clinical operates in 11 countries and has hubs in East Asia, China and India.
“With the addition of Vector Oncology’s CRO Division, we will further pursue our strategic growth objectives to provide global oncology capabilities and to extend our ability to deliver early and late-phase operational expertise and scientific leadership capabilities deeper into the U.S. and Europe,” Dr. Marisa Petersen, CEO of George Clinical, said.
According to George Clinical, there will be no disruption to the services of either organizations.